Drugs / LY2382770
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01113801 | Jul 2010 → May 2014 | diabetic kidney disease, glomerulosclerosis | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2382770 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01113801 ↗ |
| Action | Inhibit | “Transforming growth factor beta-1 inhibitor” CHEMBL2109585 ↗ |
| Route | Subcutaneous | “Subcutaneous injection given monthly for 12 months” NCT01113801 ↗ |
| Target | TGFB1 | “Transforming growth factor beta-1 inhibitor” CHEMBL2109585 ↗ |